Variable | Response |
---|---|
Length of hair (cm), median (range) | 1 (0.5–1.5) |
Hair weight (grams), mean (Standard Deviation; Range) | 2.0 (0.15; 1.76–2.28) |
Samples Below limit of quantification | |
 Atazanavir | 18 (18) |
 Ritonavir | 12 (12) |
Drug regimen: recruitment + follow-up, n (%) | |
 Tenofovir/Lamivudine/Atazanavir-ritonavir | 75 (82) |
 Abacavir/Didanosine /Atazanavir-ritonavir | 6 (7) |
 Zidovidine/Lamivudine/Atazanavir-ritonavir | 6 (7) |
 Abacavir/Lamivudine/Atazanavir-ritonavir | 3 (3) |
 Tenofovir/ Emtricitabine /Atazanavir-ritonavir | 2 (2) |
Body mass index-for-age, n (%) | |
 Normal | 25 (54) |
 Overweight | 7 (15) |
 Thinness | 14 (30) |
Age (years), mean (Standard Deviation; Range) | 15.8 (1.8; 11–18) |
Gender, n (%) | |
 Female | 27 (54) |
Caregiver, n (%) | |
 Parent | 10 (20) |
 Grandparent | 20 (40) |
 Sibling | 5 (10) |
 Aunt/uncle | 15 (30) |
Level of education, n (%) | |
 Secondary school | 39 (89) |
 Primary school | 8 (9) |
 Dropped | 1 (2) |
WHO disease progression stage, n (%) | |
 Early | 16 (32) |
 Late | 34 (68) |
Adherence by visual inspection of analogue scale, mean (Standard Deviation; Range) | 84.2 (18.1; 30–100) |
Atazanavir concentration (ng/mg), mean (Standard Deviation; Range) | 2.5 (2.0; 0.07–8.65) |
Ritonavir concentration (ng/mg), mean (Standard Deviation; Range) | 0.5 (0.4; 0.01–1.39) |